Eisai is dedicated to discovering, developing and producing innovative oncology therapies that can make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, biologic and supportive care agents for cancer across multiple indications.
Eisai Europe, Ltd.
Eisai concentrates its R&D activities in three key areas:
- Integrative Neuroscience, including: Alzheimer's disease, multiple
sclerosis, neuropathic pain, epilepsy, depression
- Integrative Oncology, including: anticancer therapies; vaccines, tumor
regression, tumor suppression, antibodies and supportive cancer
therapies; pain relief, nausea
- Vascular/Immunological reaction, including: acute coronary syndrome,
atherothrombotic disease, severe sepsis, rheumatoid arthritis,
psoriasis, Crohn's disease
In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary and Slovakia.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs approximately 11,000 employees worldwide.
For further information, please visit http://www.eisai.co.jp.
Referencias
[1] Twelves C, Akerele C, Wanders J, Cortes J. Eribulin Mesylate (E7389) vs. Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer: Subgroup Analyses from the EMBRACE Study. Abstracto 2750, presentado en el congreso ESMO, 8 de septiembre de 2010, Milán, Italia.
[2] Twelves C et al. A Phase III Study (EMBRACE) of Eribulin Mesylate vs Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane. Abstracto 1084, congreso de la American Society of Clinical Oncology (ASCO), Chicago, 2010.
[3] Coughlin, S. Breast cancer as a global health concern. Cancer Epidemiology, Octubre de 2009; 33: 315-18.
[4] Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer.2010: 46(4):765-781
[5] O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-29
[6] Kuznetsov G, Towle MJ, Cheng H, et al: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-5766
[7] Towle MJ, et al. In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B. Cancer Res 2001; 61: 1013-1021
[8] Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry.49(6):1331-1337
[9] Zhou J, Giannakakou. Targeting Microtubules for Cancer Chemotherapy. Curr Med Chem Anti-Cancer Agents. 2005:5;65-71
[10] Cancer Research UK, Breast Cancer Statistics - Key Facts [Actualizado en abril de 2010]. Disponible desde: http://info.cancerresearchuk.org/cancers... (acceso (04/08/10)
[11] Fernandez Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev.2010:36(1 ):33-42
(Debido a la longitud de esta URL podría ser necesario copiar y pegar este hiperenlace en el campo de direcciones URL de su buscador de Internet. En caso de que hubiera espacios elimínelos).
CONTACTO: Consultas de medios, Eisai Europe Ltd, Cressida Robson,+44-(0)7908-314-155; Ingenda Communications, Robyn Cabarrao,+44-(0)7913-216-896
